https://www.selleckchem.com/products/OSI-906.html
Tuberculosis followed by sarcoidosis were the two leading causes of uveitis in our group of patients. Currently, varying treatment paradigms and different clinical trial constructs preclude cross-trial comparison between different available vascular endothelial growth factor (VEGF) inhibitors. This study aimed to review the evidence and compare the efficacy of anti-VEGF therapies for neovascular age-related macular degeneration (nAMD), and to develop metrics as a means of facilitating standardized comparison between different anti-VEGF
Me gusta
Comentario
Compartir
